The present invention provides fused heterocyclicderivatives represented by the general formula:(see formula I)wherein R1 represents H, halogen, OH, etc.； R2 represents H,halogen or an alkyl group； R3 and R4 represent H, OH, halogen,etc.； Q represents alkylene, etc.； ring A represents aryl orheteroaryl； and G represents(see formula G1)or(see formula G2)or pharmaceutically acceptable salts thereof, or prodrugsthereof, which exhibit an excellent inhibitory activity in humanSGLT and are useful as agents for the prevention or treatmentof a disease associated with hyperglycemia such as diabetes,postprandial hyperglycemia, impaired glucose tolerance,diabetic complications or obesity, pharmaceutical compositionscomprising the same, and pharmaceutical uses thereof.
